Back to Clinical Trials Overview
Back To Cancer Clinical Trials
Phase I/II Study of BNC105P in Combination with Everolimus or Following Everolimus for Progressive Metastatic Clear Cell Renal Cell Carcinoma Following Prior Tyrosine Kinase Inhibitors. Hoosier Oncology Group GU09-145 (Kidney)
Principal Investigator(s): Matthew Galsky
An International Phase 3, Randomized Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (ADAPT)
Principal Investigator(s): Michael A. Palese
Back To Cancer Clinical Trials
Your search for "Kidney" returned 2 results:
Phase I/II Study of BNC105P in Combination with Everolimus or Following Everolimus for Progressive Metastatic Clear Cell Renal Cell Carcinoma Following Prior Tyrosine Kinase Inhibitors. Hoosier Oncology Group GU09-145 (Kidney)
Principal Investigator(s): Matthew Galsky
An International Phase 3, Randomized Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (ADAPT)
Principal Investigator(s): Michael A. Palese
Contact Us
Office of Research Services (ORS)
Tel: 212-824-7294
Send e-mail
Related Resources
For Patients
- Find a Mount Sinai Doctor
- Find a Mount Sinai Department or Institute
- Research Match
- Clinicaltrials.gov
- National Cancer Clinical Trials
- Video - Participating in Research - You Can Be Part of the Answer
- The Center for Information & Study on Clinical Research Participation
- Patients Like Me
For Investigators
- Office of Research Services (ORS)
- How to Post Research Projects on the Website
- Conduits
- Research Information Technology
- Communicating with Research Subjects